| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | - | - | - | - | 10.182 | 14.577 | 12.628 | 18.824 | 12.045 | 10.612 |
| Total Expenses - EUR | - | - | - | - | 10.240 | 14.762 | 14.407 | 21.918 | 21.817 | 22.008 |
| Gross Profit/Loss - EUR | - | - | - | - | -58 | -185 | -1.779 | -3.094 | -9.771 | -11.396 |
| Net Profit/Loss - EUR | - | - | - | - | -58 | -185 | -1.779 | -3.094 | -9.771 | -11.396 |
| Employees | - | - | - | - | 2 | 2 | 2 | 0 | 0 | 1 |
Check the financial reports for the company - Ovovet Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 14.481 | 28.132 | 55.561 | 112.281 | 139.400 | 191.272 |
| Current Assets | - | - | - | - | 20.768 | 7.907 | 8.913 | 21.607 | 41.020 | 13.248 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 90 | 228 | 692 | 1.082 | 1.161 | 1.371 |
| Cash | - | - | - | - | 20.678 | 7.679 | 8.220 | 20.525 | 39.859 | 11.877 |
| Shareholders Funds | - | - | - | - | 9.762 | 9.392 | 7.404 | 4.334 | -5.451 | -16.816 |
| Social Capital | - | - | - | - | 9.820 | 9.634 | 9.420 | 9.449 | 9.421 | 9.368 |
| Debts | - | - | - | - | 25.487 | 26.647 | 57.069 | 129.554 | 185.871 | 221.336 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7219 - 7219" | |||||||||
| CAEN Financial Year |
7219
|
|||||||||
Comments - Ovovet Pharma S.r.l.